Azenta CEO Marotta resigns; Madaus named interim CEO; Q4 revenue guidance reaffirmed

Azenta, Inc.

John P. Marotta resigned as President, CEO and director effective Aug 22, 2026; no disagreement with Company.
Dr. Martin Madaus, board member since 2024, appointed interim President and CEO; also principal executive officer.
Madaus is Senior Operating Executive at Carlyle Group; led Millipore sale to Merck KGaA for $7.2B.
Board reduced from 9 to 8 members; Heidrick & Struggles retained to search for permanent CEO.
Company reaffirms Q4 FY2026 total revenue guidance; adjusted EBITDA to include ~$3M one-time consulting expense.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.